Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: Results of a fixed dose study

International Urogynecology Journal

Volumn 17, Issue 3, 2006, Pages 239-247

  Hill, Simon ^a   Khullar, Vik ^b   Wyndaele, Jean Jacques ^c   Lheritier, Karine ^d  

^a DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Clinical trial; Darifenacin; Muscarinic antagonists; Urinary incontinence

Indexed keywords

DARIFENACIN; MUSCARINIC M3 RECEPTOR ANTAGONIST; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; BLADDER CAPACITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; NOCTURIA; OPTIMAL DRUG DOSE; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RESPIRATORY TRACT INFECTION; SOMNOLENCE; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE INCONTINENCE; VISUAL DISORDER; XEROSTOMIA;

EID: 33645472876     PISSN: 09373462     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00192-005-1340-3     Document Type: Article

References (30)

1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed: A population-based prevalence study. BJU Int 87(9):760-766
2. Kolta MG, Wallace LJ, Gerald MC (1984) Age-related changes in sensitivity of rat urinary bladder to autonomic agents. Mech Ageing Dev 27(2):183-188
3. Abrams P, Kelleher CJ, Kerr LA, Rogers RG (2000) Overactive bladder significantly affects quality of life. Am J Manag Care 6(11 Suppl):S580-S590
4. Andersson K-E (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3(1):46-53
5. 3 -receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 21:243-248
6. 3 receptor selectivity. Eur Urol Suppl 1:23-28
7. 3 receptor subtype. Neurourol Urodyn 21(4):A445
8. 3 antagonist for overactive bladder: Comparison with oxybutynin on ambulatory urodynamic monitoring and salivary flow. Neurourol Urodyn 20(4):A221
9. 3 selective receptor antagonist darifenacin has no clinically relevant effect on cognition and cardiac function. Prog Urol 14(Suppl. 3):22[A65]
10. Quinn P, Goka J, Richardson H (2003) Assessment of an electronic diary in patients with overactive bladder. BJU Int 91:647-652
11. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al (2002) Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21(2):167-178
12. van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A, on behalf of the Tolterodine Study Group (2001) Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder. Urology 51:414-421
13. Homma Y, Paick JS, Lee JG, Kawabe K, on behalf of the Japanese and Korean Tolterodine Study Group (2003) Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: A randomized, placebo-controlled trial. BJU Int 92:741-747
14. Cardozo L, Prescott K, Serdarevic D, Skillern L (2003) Can medication prolong warning time? Neurourol Urodyn 22(5):A74
15. Ali A, Snape J (2004) Nocturia in older people: A review of causes, consequences, assessment and management. Int J Clin Pract 58:366-373
16. Brown JS, Vittinghoff E, Wyman JF, Stone KL, Nevitt MC, Ensrud KE et al (2000) Study of Osteoporotic Fractures Research Group. Urinary incontinence: Does it increase risk for falls and fractures? J Am Geriatr Soc 48(7):721-725
17. Rosario DJ, Cutinha PE, Chapple CR, Milroy E (1996) The effects of single dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability. Eur Urol 30(Suppl 2):240[A896]
18. Appell RA (1997) Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 50(Suppl 6A):90-96
19. Gleason DM, Susset J, White C, Munoz DR, Sand PK, on behalf of the Ditropan XL Study Group (1999) Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 54(3):420-423
20. Feinberg M (1993) The problems of anticholinergic adverse effects in older patients. Drugs Aging 3(4):335-348
21. Wein AJ (2001) Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs 10(1):65-83
22. NDA 21-228-SE-8 supplement 006. BPCA Clinical Review. Detrol LA capsules (tolterodine tartrate). Available at: http://www.fda.gov/cder/foi/esum/2004/ 21228se8-006_detrol_bpca_clinicali.pdf (accessed 12 April 2005)
23. Womack KB, Heilman KM (2003) Tolterodine and memory: Dry but forgetful. Arch Neurol 60(5):771-773
24. Tsao JW, Heilman KM (2003) Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 349(23):2274-2275
25. t'Veld BA, Kwee-Zuiderwijk WJ, van Puijenbroek EP, Stricker BH (1998) Neuropsychiatric adverse effects attributed to use of oxybutynin. Ned Tijdschr Geneeskd 142(11):590-592
26. Donnellan CA, Fook L, McDonald P, Playfer JR (1997) Oxybutynin and cognitive dysfunction. BMJ 315(7119):1363-1364
27. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K (1998) Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J Am Geriatr Soc 46(1):8-13
28. Detrol LA (tolterodine tartrate extended release tablets) US prescribing information. April 2004. Available at: http://www.detrol.com/files/DetrolLA.pdf (accessed 12 April 2005)
29. Ditropan XL (oxybutynin chloride extended release tablets) US prescribing information. June 2004. Available at: http://www.orthomcneil.com/products/pi/pdfs/ditropanxl.pdf#zoom=100 (accessed 12 April 2005)
30. Sanctura (trospium chloride tablets) US prescribing information. July 2004. Available at: http://www.sanctura.com/Sanctura_Prescribing_Information.pdf (accessed 12 April 2005)